Remimazolam tosylate - Jiangsu Hengrui Medicine Co.

Drug Profile

Remimazolam tosylate - Jiangsu Hengrui Medicine Co.

Alternative Names: HR-7056; Remimazolam tosilate

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaesthesia; Sedation
  • Phase I Insomnia

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Sedation in China (IV) (NCT03003884)
  • 01 Dec 2014 Phase-II clinical trials in Anaesthesia in China (IV)
  • 01 Oct 2013 Phase-I clinical trials in Insomnia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top